FTC Settles Complaint Over Deceptive Marketing of Unapproved Cancer Products
By Michael Mezher -
Published 12 January 2018
The US Federal Trade Commission (FTC) on Thursday announced it has reached a settlement with CellMark Biopharma related to the company's claims about marketing efforts to sell two of its unapproved products.
Categories: News, US, FDA, FTC, Advertising and Promotion
Tags: FTC, Federal Trade Commission, CellMark